Phospho-PTK2 (Tyr576) Antibody

Shipped with Ice Packs
In Stock

Product Specs

Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship the products within 1-3 business days of receiving your order. The delivery time may vary depending on the purchase method or location. For specific delivery times, please consult your local distributors.
Synonyms
FADK 1 antibody; FADK antibody; FAK related non kinase polypeptide antibody; FAK1 antibody; FAK1_HUMAN antibody; Focal adhesion kinase 1 antibody; Focal adhesion Kinase antibody; Focal adhesion kinase isoform FAK Del33 antibody; Focal adhesion kinase related nonkinase antibody; FRNK antibody; p125FAK antibody; pp125FAK antibody; PPP1R71 antibody; Protein phosphatase 1 regulatory subunit 71 antibody; Protein tyrosine kinase 2 antibody; Protein-tyrosine kinase 2 antibody; Ptk2 antibody; PTK2 protein tyrosine kinase 2 antibody
Target Names
Uniprot No.

Target Background

Function
Focal Adhesion Kinase 1 (FAK1) is a non-receptor protein-tyrosine kinase that plays a crucial role in regulating a variety of cellular processes. These include cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation, and apoptosis. FAK1 is essential for early embryonic development and placenta development. It is also required for embryonic angiogenesis, normal cardiomyocyte migration and proliferation, and normal heart development. Furthermore, FAK1 regulates axon growth and neuronal cell migration, axon branching, and synapse formation; it is required for normal development of the nervous system. Additionally, FAK1 plays a role in osteogenesis and differentiation of osteoblasts. FAK1 functions in integrin signal transduction, but also in signaling downstream of numerous growth factor receptors, G-protein coupled receptors (GPCR), EPHA2, netrin receptors, and LDL receptors. Upon activation, FAK1 forms multisubunit signaling complexes with SRC and SRC family members. This leads to the phosphorylation of additional tyrosine residues, creating binding sites for scaffold proteins, effectors, and substrates. FAK1 regulates numerous signaling pathways. It promotes activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascade. It also promotes activation of MAPK1/ERK2, MAPK3/ERK1, and the MAP kinase signaling cascade. FAK1 promotes localized and transient activation of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs), thereby modulating the activity of Rho family GTPases. Signaling via CAS family members mediates activation of RAC1. FAK1 recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates P53/TP53 activity, P53/TP53 ubiquitination, and proteasomal degradation. FAK1 phosphorylates SRC, which increases SRC kinase activity. It also phosphorylates ACTN1, ARHGEF7, GRB7, RET, and WASL. FAK1 promotes phosphorylation of PXN and STAT1; most likely PXN and STAT1 are phosphorylated by a SRC family kinase that is recruited to autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. FAK1 promotes phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and PTK2/FAK1. FAK1 promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK) does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its enhanced expression can attenuate the nuclear accumulation of LPXN and limit its ability to enhance serum response factor (SRF)-dependent gene transcription.
Gene References Into Functions
  1. LFA-1 cross-linking recruits and activates FAK1 and PYK2 to phosphorylate LAT selectively on a single Y-171 site that binds to the GRB2-SKAP1 complex and limits dwell times of T-cells with dendritic cells. PMID: 28699640
  2. Research has identified FAK mRNA as a direct target of miR-433. Its activation inhibits the effect of microRNA433 on the growth of cervical cancer cells. PMID: 30272334
  3. This study demonstrates that Leu33Pro polymorphism of integrin beta 3 modulates platelet Src pY418 and focal adhesion kinase pY397 phosphorylation in response to abnormally high shear stress. While physiological shear stress does not affect platelet signaling, abnormally high shear stress considerably elevates Src and FAK phosphorylation in both Pro33 and Leu33 platelets. PMID: 29965811
  4. High FAK expression is associated with gastric cancer. PMID: 30106432
  5. These results indicate that PCTK3 controls actin cytoskeleton dynamics by negatively regulating the FAK/Rho signaling pathway. PMID: 28361970
  6. Data suggest that FAK is required for adipocyte survival and maintenance of insulin sensitivity, particularly in the context of adipose tissue expansion as a result of caloric excess. PMID: 28165007
  7. Data suggest that TYRO3-mediated phosphorylation of ACTN4 is involved in invasiveness of melanoma cells; TYRO3-mediated phosphorylation of ACTN4 requires FAK activation at tyrosine 397. (TYRO3 = TYRO3 protein tyrosine kinase; ACTN4 = actinin alpha 4; FAK = focal adhesion kinase isoform FAK1) PMID: 29274473
  8. FAK controls invasiveness of tumor cells by regulating focal adhesion-mediated motility. PMID: 29133485
  9. FAK controls the nuclear translocation and activation of YAP in response to mechanical activation and suggests that the YAP-dependent process of durotaxis requires a cell with an asymmetric distribution of active and inactive FAK molecules. PMID: 29070586
  10. Results show that the proto-Oncogene Protein ets-1 (ETS1) drives ovarian cancer (OC) metastasis phenotypes through its transcriptional target PTK2 (focal adhesion kinase FAK). PMID: 29174800
  11. Methylmercury chloride negatively affects the activation of Src, Rac1, and Cdc42, all of which are critical proteins for the regulation of cell movement. PMID: 29197552
  12. This study demonstrated that the Cas scaffolding protein family member 4 and protein tyrosine kinase 2 proteins play a significant role in the activation of downstream signaling pathways in Alzheimer's disease. PMID: 29789968
  13. Calpain small subunit 1 (Capn4) overexpression increased the protein level of cleaved talin and activated the focal adhesion kinase (FAK)/AKT/MAPK signaling in 786-O cells, while Capn4 silencing decreased the protein level of cleaved talin in Caki-1 cells. PMID: 29648579
  14. Mitochondria are present at the leading edge of migrating cells, and SIRT3 expression is down-regulated during migration, resulting in elevated ROS levels. This SIRT3-mediated control of ROS represses Src oxidation and attenuates focal adhesion kinase (FAK) activation. PMID: 29915029
  15. These results demonstrated that the inhibition of FAK promoted cell detachment by decreasing the expression of focal adhesions components (talin and paxillin), and inhibiting cell motility by reducing the levels of Rho GTPases (Rac1, Cdc42, and RhoA). PMID: 29484384
  16. The results showed that in cervical cancer cells Rac1 activation by hypoxia could stimulate invasion and migration, and this process was mediated by integrin a5b3-facilitated FAK and PI3K phosphorylation. PMID: 29358562
  17. MUC4/X facilitated pancreatic cancer (PC) tumorigenesis via integrin-beta1/FAK/ERK signaling pathway. Overall, these findings revealed the novel role of MUC4/X in promoting and sustaining the oncogenic features of PC. PMID: 29777904
  18. The addition of LCS to capecitabine treatment led to an increase in the proteolysis of the FAK signaling cascade components. PMID: 30061234
  19. MPAP suppressed cancer cell proliferation and the phosphorylation of FAK1. Combined treatment with MPAP and irradiation (IR) showed enhanced suppression of cancer cell proliferation in wild-type p53 cells and more intense suppression in p53-null cells. PMID: 29048635
  20. Optogenetic control of FAK signaling has been described. PMID: 29074139
  21. Results suggest that W2 suppresses cancer cell migration and invasion by inhibiting FAK/STAT3 signaling and STAT3 translocation to the nucleus in monomorphic malignant human glioma cells. PMID: 28498494
  22. These results suggest that Ascochlorin inhibits cell migration and invasion by blocking FAK and JAK/STAT signaling, resulting in reduced MMP-2 activity. PMID: 28569433
  23. High levels of phosphorylated tyrosine-397 FAK in the nucleus of patient-derived melanoma tissues. PMID: 28348210
  24. The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK. PMID: 28928239
  25. The ectopic overexpression of miR-379 inhibited cell migration, invasion, and EMT progress, while downregulated miR-379 reversed the effect. Additionally, miR-379 regulated the focal adhesion kinase (FAK) by directly binding to its 3'-UTR, resulting in suppression of AKT signaling. In clinical samples of gastric cancer (GC), miR-379 inversely correlated with FAK, which was upregulated in GC. PMID: 28713929
  26. Building upon previous work suggesting that FAK-Akt1 binding is mediated by the FAK F1 lobe, researchers demonstrated that independently expressing the F1 domain in human Caco-2 or murine CT-26 colon cancer cells by transient or stable inducible plasmid expression respectively prevents the stimulation of cancer cell adhesion by increased extracellular pressure. PMID: 28820394
  27. Functional activation of FAK1 in metastases and provide preclinical rationale for targeting this kinase in the setting of advanced ccRCC. PMID: 28418903
  28. This study shows that simultaneous deactivation of FAK and Src improves the pathology of hypertrophic scar. PMID: 27181267
  29. Silencing of p130Cas and inhibition of FAK activity both strongly reduced imatinib and nilotinib stimulated invasion. PMID: 27293031
  30. IP6K1 physiologically regulates neuronal migration by binding to alpha-actinin and influencing phosphorylation of both FAK and alpha-actinin through its product 5-diphosphoinositol pentakisphosphate. PMID: 28154132
  31. These data indicate that Ang II-AT2R regulates human bone marrow MSC migration by signaling through the FAK and RhoA/Cdc42 pathways. PMID: 28697804
  32. Upregulated FAK expression correlates with poor prognosis and tumor dissemination in surgically treated patients with hypopharyngeal cancer. PMID: 27061113
  33. These findings suggest that the integrin beta4-FAK/Src signaling axis may play a crucial role in clonorchiasis-associated cholangiocarcinoma metastasis during tumor progression. PMID: 28286026
  34. Whereas Src activation under shear stress is dominantly ligand-dependent, FAK signaling seems to be mostly shear induced. PMID: 27467982
  35. The miR-7 can inhibit the activation of ERK/MAPK signaling pathway by down-regulating FAK expression, thereby suppressing the proliferation, migration, and invasion of NSCLC cells. The miR-7 and its target gene FAK may be novel targets for the diagnosis and treatment of NSCLC. PMID: 27764812
  36. Thrombomodulin (TM) promotes angiogenesis by enhancing cell adhesion, migration, and FAK activation through interaction with fibronectin. PMID: 27602495
  37. FAK activation may facilitate tumor initiation by causing resistance to apoptosis. PMID: 27611942
  38. Among a group of tumor cells, there is a correlation between activation of the MRTF-dependent transcription and activated FAK-dependent regulation of cell migration. PMID: 27708220
  39. Our study suggests that FOXM1 transcription factor regulates Integrin b1 gene expression and that the FOXM1/ Integrin-b1/FAK axis may play an important role in the progression of Triple-negative breast cancer. PMID: 28361350
  40. It has been demonstrated that FAK depletion reduces hepatocellular carcinoma cell growth by affecting cancer-promoting genes including the pro-oncogene EZH2. PMID: 28338656
  41. High FAK expression is associated with breast cancer cell invasion, transendothelial migration, and metastasis. PMID: 26993780
  42. Study provides evidence that PTK2 expression is regulated by KCNMA1 in gastric tumorigenesis. PMID: 28231797
  43. HER2 reduces the radiosensitivity of breast cancer by activating Fak in vitro and in vivo. PMID: 27286256
  44. The interaction between FAK and tetraspan proteins in physiological and pathological conditions is reviewed. PMID: 27279237
  45. BKCa has a role in promoting growth and metastasis of prostate cancer through facilitating the coupling between alphavbeta3 integrin and FAK. PMID: 27233075
  46. Proteomic analysis identified PTK2/FAK overexpression as a biomarker of radioresistance in locally advanced HNSCC, and PTK2/FAK inhibition radiosensitized HNSCC cells. PMID: 27036135
  47. The FAK-Src-Paxillin system is a marker of unfavorable prognosis for human Neuroblastoma patients but also a promising therapeutic target. PMID: 29040002
  48. IGF-II siRNA inactivates the FAK/PI3K/Akt signaling pathway, and further reduces cell proliferation, N-ras, and C-myc levels in SMMC-7721 cells. PMID: 27768959
  49. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancer patients. GSK2256098 has an acceptable safety profile, has evidence of target engagement at doses at or below the MTD, and has clinical activity in patients with mesothelioma, particularly those with merlin loss. PMID: 27733373
  50. Studies suggest that signaling pathways downstream of activated FAK, including paxillin, will be important to study in the context of FAK inhibition and other therapeutics to identify novel biomarkers. PMID: 26980710

Show More

Hide All

Database Links

HGNC: 9611

OMIM: 600758

KEGG: hsa:5747

STRING: 9606.ENSP00000341189

UniGene: Hs.395482

Involvement In Disease
Aberrant PTK2/FAK1 expression may play a role in cancer cell proliferation, migration and invasion, in tumor formation and metastasis. PTK2/FAK1 overexpression is seen in many types of cancer.
Protein Families
Protein kinase superfamily, Tyr protein kinase family, FAK subfamily
Subcellular Location
Cell junction, focal adhesion. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cell cortex. Cytoplasm, cytoskeleton. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus. Cytoplasm, cytoskeleton, cilium basal body. Note=Constituent of focal adhesions. Detected at microtubules.
Tissue Specificity
Detected in B and T-lymphocytes. Isoform 1 and isoform 6 are detected in lung fibroblasts (at protein level). Ubiquitous. Expressed in epithelial cells (at protein level).

Q&A

What is the biological significance of FAK phosphorylation at Tyr576?

Phosphorylation of FAK at Tyr576 represents a critical step in the activation mechanism of this non-receptor protein tyrosine kinase. While Tyr397 serves as the primary autophosphorylation site, phosphorylation at Tyr576/577 within the activation loop is required for full catalytic activity of FAK. This phosphorylation occurs following FAK activation through integrin signaling in adherent cells .

The phosphorylation process follows a specific sequence: initial autophosphorylation at Tyr397 creates a binding site for SRC and SRC family members, which subsequently leads to phosphorylation at Tyr576/577 and additional tyrosine residues . Notably, certain kinases demonstrate site-specific phosphorylation patterns - for example, FGR specifically promotes phosphorylation at both Tyr397 and Tyr576, while FER targets Tyr577, Tyr861, and Tyr925 .

Tyrosine 576 phosphorylation status serves as a reliable biomarker for active FAK-mediated signaling and is particularly important in contexts like cell migration, adhesion, and cancer metastasis .

What are the optimal applications and protocols for Phospho-PTK2 (Tyr576) antibodies?

Phospho-PTK2 (Tyr576) antibodies demonstrate effectiveness across several key experimental applications:

Western Blotting (WB):

  • Recommended dilution range: 1:500-1:2000

  • Expected molecular weight: 119-125 kDa

  • Sample preparation: Include phosphatase inhibitors in lysis buffers

  • Controls: Include non-phosphorylated controls or blocking peptide samples

Immunohistochemistry (IHC):

  • Recommended dilution range: 1:100-1:300

  • Fixation method: Compatible with formalin-fixed, paraffin-embedded tissues

  • Detection system: Use high-sensitivity detection systems for optimal results

Immunofluorescence (IF):

  • Recommended dilution range: 1:50-1:200

  • Cell preparation: Methanol fixation has shown good results with HeLa cells

  • Counterstaining: DAPI for nuclear visualization is recommended

Cell-Based ELISA:

  • Provides qualitative determination of FAK (phospho Tyr576) expression

  • Multiple normalization methods available: anti-GAPDH antibody control, Crystal Violet whole-cell staining, and total FAK normalization

How can I verify the specificity of Phospho-PTK2 (Tyr576) antibodies?

Validating antibody specificity is crucial for obtaining reliable research results. Several approaches are recommended:

  • Blocking peptide competition assays: Pre-incubate the antibody with the phosphorylated peptide immunogen. This should abolish specific binding in Western blots or other applications, as demonstrated in validation studies .

  • Phosphatase treatment: Compare samples treated with and without lambda phosphatase. Specific phospho-antibody reactivity should be eliminated after phosphatase treatment.

  • Stimulation experiments: Use known activators of FAK phosphorylation (e.g., PMA treatment in HT29 cells) to demonstrate increased antibody reactivity .

  • Cross-reactivity assessment: Confirm the antibody detects endogenous levels of FAK protein only when phosphorylated at Y576, with no cross-reactivity with other proteins or non-phosphorylated forms .

  • Knockout/knockdown verification: Compare signals between wild-type cells and those where FAK has been depleted to confirm signal specificity.

Commercial antibodies targeting Phospho-PTK2 (Tyr576) vary in several important aspects:

Host Species and Format:

Most commonly rabbit-derived (polyclonal or monoclonal) , with recombinant monoclonal options now available for enhanced reproducibility .

Immunogen Design:

Typically produced against synthesized peptides derived from human FAK surrounding the Tyr576 phosphorylation site, often covering amino acids 542-591 .

Validated Applications:

While most antibodies are validated for Western blotting, application breadth varies considerably between products, with some validated for multiple techniques including IF, IHC, IP, and ELISA .

Formulation:

Most commonly provided in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide .

Species Reactivity:

Most antibodies react with human, mouse, and rat samples due to high sequence conservation around the Tyr576 site .

High Background in Western Blots:

  • Issue: Non-specific bands or smearing

  • Solutions: Increase blocking time and concentration; use alternative blocking agents (milk vs. BSA); optimize antibody dilution; increase washing duration and frequency; add low concentrations of detergent to wash buffers .

Weak or Absent Signal:

  • Issue: No detection of phosphorylated protein

  • Solutions: Verify phosphorylation status through positive controls; confirm adequate sample preparation with phosphatase inhibitors; use enhanced chemiluminescence detection; ensure appropriate transfer conditions for high molecular weight FAK (125 kDa) .

Inconsistent Results:

  • Issue: Variable detection across experiments

  • Solutions: Standardize cell culture conditions known to affect FAK phosphorylation; maintain consistent lysis protocols; avoid freeze-thaw cycles of both samples and antibody; use freshly prepared samples when possible .

Non-specific Binding in Immunohistochemistry/Immunofluorescence:

  • Issue: Diffuse staining or unexpected localization

  • Solutions: Optimize fixation methodology; perform antigen retrieval; include appropriate blocking steps; validate with phosphopeptide competition .

How does phosphorylation at Tyr576 interact with other FAK phosphorylation sites?

FAK contains multiple phosphorylation sites that function in a coordinated manner:

Phosphorylation Sequence and Interdependence:

Tyr397 serves as the primary autophosphorylation site, creating a binding site for SRC family kinases, which subsequently phosphorylate Tyr576/577 . This sequential activation is critical for full FAK activity.

Site-Specific Functions:

  • Tyr397: Initial autophosphorylation; binding site for SH2 domain-containing proteins including SRC, PIK3R1, and SHC1

  • Tyr576/577: Located in the activation loop; required for maximum kinase activity

  • Tyr861: Associated with SRC-mediated phosphorylation and FAK conformational changes

  • Tyr925: Creates binding site for Grb2; implicated in the MAPK pathway

Temporal Dynamics:

While Tyr397 phosphorylation can occur rapidly upon integrin engagement, Tyr576 phosphorylation follows as a secondary event dependent on SRC recruitment. Both Tyr397 and Tyr576 phosphorylation are primarily observed in adherent cells, alongside Ser722 phosphorylation .

Specialized Kinase Interactions:

Different kinases show preferences for specific FAK phosphorylation sites. For example, FER can phosphorylate Tyr577, Tyr861, and Tyr925 even in non-adherent cells, while RET directly phosphorylates FAK at Tyr576/577 but not Tyr925 .

Multiplex Phosphorylation Analysis:

Researchers are utilizing antibody duos (e.g., pY576/577 paired with pY925) to simultaneously track multiple FAK phosphorylation events, providing insight into activation mechanisms and signaling dynamics .

Quantitative Phosphoproteomics:

Combining immunoprecipitation using Phospho-PTK2 (Tyr576) antibodies with mass spectrometry to identify phosphorylation-dependent protein interactions and quantify phosphorylation stoichiometry .

Cell-Based ELISA Systems:

Specialized ELISA kits allow for the detection of FAK (phospho Tyr576) in intact cells, enabling studies of how different stimulation conditions affect FAK phosphorylation across various cell lines .

Cancer Biomarker Studies:

Increased levels of phosphorylated FAK at Tyr576 are being investigated as potential biomarkers in various cancers, with researchers exploring correlations with tumor progression, metastasis, and therapeutic response .

Proximity Ligation Assays:

This advanced technique allows visualization of protein-protein interactions involving phosphorylated FAK, providing spatial information about where activated FAK functions within cells .

How can I quantitatively assess FAK Tyr576 phosphorylation relative to total FAK?

Accurate quantification of phosphorylation status requires normalization to total protein levels:

Western Blot Quantification:

  • Run duplicate samples on parallel gels or strip and reprobe membranes

  • Probe one with phospho-specific antibody and the other with total FAK antibody

  • Calculate the ratio of phospho-FAK to total FAK using densitometry

  • Include loading controls (e.g., GAPDH, β-actin) for additional normalization

Normalization in Cell-Based Assays:

Multiple normalization methods are available for cell-based ELISA systems:

  • Anti-GAPDH antibody serves as an internal positive control

  • Crystal Violet whole-cell staining determines cell density to adjust for plating differences

  • Anti-FAK antibody provides normalization by comparing absorbance values for phosphorylated vs. non-phosphorylated target

Data Visualization:

Present data as fold change in phosphorylation rather than absolute values to account for experimental variation. Include statistics from multiple independent experiments to establish significance of observed changes.

What is the role of FAK Tyr576 phosphorylation in cancer and other pathological conditions?

FAK Tyr576 phosphorylation status has significant implications in disease contexts:

Cancer Research:

Increased levels of FAK and Src proteins are found in tumors, with the FAK-Src signaling complex playing a crucial role in tumor cell behavior. Phosphorylation of FAK at Tyr576/577 is essential for this activity and may serve as a biomarker for cancer progression .

Metastasis:

As a key regulator of cell migration, adhesion, and invasion, phosphorylated FAK at Tyr576 is implicated in the metastatic cascade. FAK activation promotes focal adhesion turnover and cytoskeletal reorganization necessary for cell movement .

Therapeutic Targeting:

FAK inhibitors are being developed as potential cancer therapeutics, with Tyr576 phosphorylation serving as a pharmacodynamic marker of drug efficacy. Monitoring this phosphorylation site helps researchers evaluate the impact of FAK-targeting compounds .

Research Models:

Phospho-specific antibodies against FAK Tyr576 are being used to investigate FAK activation in various experimental models including 2D and 3D cell cultures, xenografts, and tissue microarrays, providing insights into the spatial and temporal dynamics of FAK activation in different microenvironments .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.